VISTA 16: anti-inflammatory agent in acute coronary syndromes

There is evidence that inflammation would have an impact on the prognosis of patients experiencing acute coronary syndromes. The phospholipase A2 inhibitor Varespladib has positive effects on lipid and inflammatory markers.

This double-blind, multicenter planned to randomize 5145 patients with acute coronary syndrome to Varespladib or placebo. The primary endpoint was a combination of cardiovascular mortality, myocardial infarction, stroke, and unstable angina requiring hospitalization. In a pre- specified interim analysis 212 events were observed so suspension of the study was recommended for possible damage. Varespladib was associated with an increased risk of myocardial infarction (3.4 % versus 2.2 %, HR 1.66; CI 95%: 1,16-2, 39 9; p = 0.005).

Conclusion:

In patients with recent acute coronary syndrome Varespladib did not reduce the events and actually increase the risk of myocardial infarction.

7_stephen_nicholls
Stephen Nicholls
2013-11-18

Original title: Varespladib and Cardiovascular Events in Patients With an Acute Coronary Syndrome.

More articles by this author

TOPCAT: Spironolactone in heart failure with preserved ejection fraction

The aldosterone blockade has shown benefit in the treatment of heart failure with systolic dysfunction after stroke. The aim of this study was to...

Plastic versus mitral valve replacement in ischemic mitral regurgitation

Unlike degenerative mitral insufficiency, ischemic failure is due to an increase in the left ventricular cavity, the loss of its elliptical form, ring dilation...

MINERVA trial: DDDR versus DDDRP-MVP in patients with bradycardia

The sinus node disease is approximately 50 % of pacemaker implants. Atrial fibrillation is a frequent comorbidity of pacemakers and is associated with heart...

HF ROSE: Dopamine and Neseritide in heart failure associated with renal dysfunction

Previous small studies have suggested that low-dose dopamine or neseritide can enhance congestive signs of acute heart failure without altering renal function. 360 patients...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....